Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approachThis appointment underlines the importance of the bioactive...
-
L’USAMRIID (United States Army Medical Research Institute of Infectious Diseases) evaluated DNV3681 against Bacillus anthracis that triggers anthrax and Francisella tularensis that triggers tularemia...
-
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837 Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic...
-
DEINOVE has developed a unique bioproduction process that leads to the first 100% pure Phytoene with an anti-aging action which mechanism of action has been discovered and reveals a target of choice...
-
Georges GAUDRIAULT, Scientific Director of DEINOVE, will give a talk at the ECCMID, at the ‘Therapeutics pipeline corner’, on this coming Sunday, April 14th, in Amsterdam.He will describe the progress...
-
Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur to explore the potential of new targeted strains The Institut Pasteur will provide a selection of strains for the DEINOVE...
-
Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium difficile, expected to begin Phase II in mid-2019Successful...
-
DEINOVE passes the first milestone of the AGIR programm and receives €1.5m from Bpifrance The robotic platform for extracting and screening antibiotic activities from bacterial strains is now...
-
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer...
-
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in...